Literature DB >> 19350508

[Association of single nucleotide polymorphisms in VEGF gene with the risk of endometriosis and adenomyosis].

Qing Liu1, Yan Li, Jian Zhao, Rong-miao Zhou, Na Wang, Dong-lan Sun, Ya-nan Duan, Shan Kang.   

Abstract

OBJECTIVE: To investigate the association of single nucleotide polymorphisms (SNPs) in VEGF gene with the risk of endometriosis and adenomyosis.
METHODS: Genotypes were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method in 344 endometriosis patients, 174 adenomyosis patients, 360 frequency-matched control women of endometriosis and 199 frequency-matched control women of adenomyosis.
RESULTS: No significant difference was found in allele frequencies and genotype distributions of the -460C/T polymorphism between patients (endometriosis and adenomyosis) and control women (all P value > 0.05). However, there were significant differences in genotype and allele distributions of the VEGF -1154G/A polymorphism between patients (endometriosis and adenomyosis) and control women (all P value < 0.05). The genotype frequencies of the VEGF -1154 AA, GA, and GG in endometriosis patients and control women were 1.7%, 28.8%, 69.5% and 5.8%, 32.8%, 61.4%, respectively; and the A and G allele frequencies in the two groups were 16.1%, 83.9% and 22.2%, 77.8%, respectively. The genotype frequencies of the VEGF -1154 AA, GA, and GG in adenomyosis patients and control women were 2.9%, 23.6%, 73.6% and 7.0%, 34.2%, 58.8%, respectively; and the A and G allele frequencies in the two groups were 14.7%, 85.3% and 24.1%, 75.9% respectively. Compared with GA+ AA genotype, GG genotypes could significantly increase the risk of endometriosis (OR:1.43,95%CI:1.05-1.96) and adenomyosis (OR:1.95,95%CI:1.26-3.03).
CONCLUSION: The VEGF -1154G/A polymorphism was associated with susceptibility to endometriosis and adenomyosis, and the GG genotype could significantly increase the risk of developing endometriosis and adenomyosis. However, the VEGF -460C/T polymorphism was not associated with susceptibility to endometriosis and adenomyosis in the population studied.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19350508     DOI: 10.3760/cma.j.issn.1003-9406.2009.02.010

Source DB:  PubMed          Journal:  Zhonghua Yi Xue Yi Chuan Xue Za Zhi        ISSN: 1003-9406


  5 in total

1.  Adenomyosis: Mechanisms and Pathogenesis.

Authors:  Junyu Zhai; Silvia Vannuccini; Felice Petraglia; Linda C Giudice
Journal:  Semin Reprod Med       Date:  2020-10-08       Impact factor: 1.303

2.  Role of vascular endothelial growth factor polymorphisms (-2578C>A, -460 T>C, -1154G>A, +405G>C and +936C>T) in endometriosis: a case-control study with Brazilians.

Authors:  Jamila Alessandra Perini; Jessica Vilarinho Cardoso; Plínio Tostes Berardo; Rosane Vianna-Jorge; Luiz Eurico Nasciutti; Marta Bellodi-Privato; Daniel Escorsim Machado; Mauricio Simões Abrão
Journal:  BMC Womens Health       Date:  2014-09-26       Impact factor: 2.809

3.  Co-existence of benign gynecological tumors with endometriosis in a group of 1,000 women.

Authors:  Charoula Matalliotaki; Michail Matalliotakis; Panagiotis Ieromonachou; George N Goulielmos; Maria I Zervou; Aggelos Laliotis; Demetrios A Spandidos; Aydin Arici; Ioannis Matalliotakis
Journal:  Oncol Lett       Date:  2017-11-20       Impact factor: 2.967

4.  Insights into Assessing the Genetics of Endometriosis.

Authors:  Nilufer Rahmioglu; Stacey A Missmer; Grant W Montgomery; Krina T Zondervan
Journal:  Curr Obstet Gynecol Rep       Date:  2012-06-15

5.  Epidemiological aspects of the outcomes from the treatment of endometriosis: Experience from two different geographical areas.

Authors:  Charoula Matalliotaki; Michail Matalliotakis; Maria I Zervou; Athina Patelarou; Ioannis Koliarakis; Demetrios A Spandidos; Aydin Arici; Ioannis Matalliotakis; George N Goulielmos
Journal:  Exp Ther Med       Date:  2019-12-05       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.